Data and publications reflect potential of REL-1017.

Our successful Phase 1 and 2 studies of REL-1017, combined with the Relmada’s team appreciation of the urgent need for additional effective and rapid-acting treatments, are fueling our swift execution of upcoming registration studies focused on major depressive disorder (MDD). Learn more about our results to date.